Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.
- Kristina Dunder, Pieter A de Graeff, Eberhard Blind
- European Heart Journal - Cardiovascular Pharmacotherapy, April 2017, Oxford University Press (OUP)
- DOI: 10.1093/ehjcvp/pvx006